However, the reduction in the expression of a survival factor such as AMPKα1 in cardiomyocytes may provide unfavorable environments for cancer patients, and a combination therapy involving melatonin and doxorubicin requires careful analyses of their effects on cardiomyocytes as well as on cancer cells. Here, PRKAA1 is linked to cancer.